ARTICLE SUMMARY:
David Caumartin, CEO of RebrAIn talked to MedTech Strategist about his company’s progress developing and commercializing a supervised artificial intelligence system that improves the precision of neurosurgery for movement disorders.
2025 was a big year for RebrAIn and its OptimMRI software, a supervised artificial intelligence that identifies precise neuromodulation targets.
